We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 23, 2022

Effect of Rivaroxaban Monotherapy vs Combination Therapy on Thrombotic and Bleeding Events in Patients With AF and Stable CAD

JAMA Cardiology

 

Additional Info

JAMA Cardiology
Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial
JAMA Cardiol 2022 Jun 15;[EPub Ahead of Print], R Naito, K Miyauchi, S Yasuda, K Kaikita, M Akao, J Ako, T Matoba, M Nakamura, N Hagiwara, K Kimura, A Hirayama, K Matsui, H Ogawa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading